|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-12-31 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1975-05-02 |
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).
A two stage, epidemiological, cross-sectional survey study of the Australian population, to determine the prevalence and severity of Hidradenitis Suppurativa (HS).
Hurley staging versus self administered questionnaire to determine the severity of Hydradentitis Suppurativa
100 项与 AbbVie (Pty) Ltd. (South Africa) 相关的临床结果
0 项与 AbbVie (Pty) Ltd. (South Africa) 相关的专利(医药)
100 项与 AbbVie (Pty) Ltd. (South Africa) 相关的药物交易
100 项与 AbbVie (Pty) Ltd. (South Africa) 相关的转化医学